Freenome
Pioneering early cancer detection through innovative next-generation blood tests using Freenome's multiomics platform.
Freenome is a groundbreaking biotech company based in South San Francisco that utilizes a multiomics platform to develop next-generation blood tests for early cancer detection. Dedicated to making early cancer detection accessible, Freenome's team is committed to decoding the means to cancer's end through rigorous research and clinical evidence. Their focus on accessibility aims to identify cancer in its earliest stages while also engaging in partnerships and offering career opportunities.
About Freenome
Freenome is a pioneering biotech company that develops next-generation blood tests for early cancer detection. Leveraging their innovative multiomics platform, Freenome is moving early cancer detection forward, making it accessible to all. Based in South San Francisco, the team at Freenome is dedicated to decoding the means to cancer's end through clinical evidence and rigorous research. With a strong focus on accessibility, Freenome's early cancer detection blood tests aim to identify cancer in its earliest, most treatable stages. The company's commitment extends beyond their products, as they actively engage in partnerships and offer career opportunities in the field.
